CD19-targeted chimeric antigen receptor (CAR)-T-cell immunotherapy has shown remarkable efficacy in relapsed and/or refractory (r/r) CD19+ B-cell malignancies including diffuse large B-cell lymphoma (DLBCL) [1]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.